74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Omeros Corp
Closed
Sector Healthcare
9.2 -3.87
Overview
Share price change
24h
Min
9.19
Max
9.36
Income | 24M -32M |
|---|---|
EPS | -0.64 |
Profit margin | -3,210.102 |
Employees | 198 |
EBITDA | -33M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +129.08 upside |
Next Earnings | 31 Mar 2025 |
|---|
Market Cap | 320M 536M |
|---|---|
Previous open | 13.07 |
Previous close | 9.2 |
News Sentiment
By Acuity
25%
75%
43 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Bullish Evidence
Omeros Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Omeros Corp Forecast
Price Target
By TipRanks
129.08% upside
12 Months Forecast
Average 21.03 USD 129.08%
High 36 USD
Low 6.069 USD
Based on 3 Wall Street analysts offering 12 month price targets forOmeros Corp - Dist in the last 3 months.
Sentiment
By Acuity
43 / 393 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Omeros Corp
Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its lead drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens replacement for adult and pediatric patients. Its drug candidate narsoplimab is the subject of a biologics license application (BLA) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). It also has multiple Phase III and Phase II clinical-stage development programs in its pipeline, which are focused on complement-mediated disorders, including immunoglobulin A (IgA) nephropathy, atypical hemolytic uremic syndrome (aHUS) and COVID-19.
